Metformin
Metformin hydrochloride (biguanide)
Written by Aaron CuhaReviewed Sep 2026
Also known as: Glucophage, Metformin HCl, dimethylbiguanide
The most discussed drug in longevity, with enormous human safety data and a geroscience record that is consistently null. It also blunts the muscle and fitness gains from training.
Overview
Metformin is a first-line diabetes drug taken by tens of millions of people, with sixty years of safety data behind it. Its reputation as an anti-ageing drug rests mainly on one 2014 observational analysis reporting that people taking it outlived non-diabetic controls, a result that two later attempts to replicate found pointing the other way. In the NIA Interventions Testing Program, which runs the same protocol across three independent sites, metformin did not significantly extend lifespan in either sex. The largest and longest human dataset, 21 years of follow-up in the Diabetes Prevention Program Outcomes Study, is null on all-cause mortality, cancer incidence and mortality, cardiovascular mortality, major cardiac events and frailty. Nothing here says metformin is a bad diabetes drug, because it is a very good one. It says the case for taking it to slow ageing has not been made, and the trial designed to test that question has still not started.
Mechanism of action
Inhibits mitochondrial complex I and activates AMPK, reducing hepatic glucose output and improving insulin sensitivity. The AMPK account is incomplete and the relative contribution of complex I inhibition, mitochondrial glycerophosphate dehydrogenase and gut-mediated effects is actively disputed between research groups.
Human evidence
Extensive for diabetes, essentially absent for ageing. Metformin has been given to tens of millions of people and studied in randomised trials for decades, and almost none of those trials asked a geroscience question.
- Decades of randomised trials in diabetes and prediabetes, where metformin's benefits on glucose control and progression to diabetes are well established. None of those trials was designed around an ageing endpoint.
- MASTERS, randomised and double-blind in 94 adults over 65: the placebo group gained more muscle from 14 weeks of supervised resistance training than the metformin group did.
- Konopka and colleagues, randomised and double-blind in 53 older adults: metformin reduced the gains in insulin sensitivity and cardiorespiratory fitness produced by 12 weeks of aerobic training.
- TAME, the trial designed specifically to test metformin as a geroscience drug in 3,000 adults aged 65 to 79, has no ClinicalTrials.gov registration as of September 2026. We searched the registry directly rather than relying on secondary reports.
What this does not tell you: Everything above concerns people with diabetes or prediabetes, or short training studies in healthy older adults. No randomised trial has tested metformin for lifespan or healthspan in metabolically healthy people, which is the population most interested in taking it for that purpose.
Reading the research record
Metformin is the clearest case on this site of a reputation built on observational data that did not survive replication. The 2014 analysis reporting that metformin users outlived matched non-diabetic controls was striking enough to launch the modern geroscience conversation, and it carries several structural biases that all push in the same direction, including immortal time bias, differential censoring when treatment is intensified, and a comparator group selected in a way that favours the drug. Two independent replication attempts, one using Danish national registries and discordant twins and one following a Welsh cohort for 20 years, found survival running the other way.
The animal record is similarly softer than its reputation. A 2013 study in C57BL/6 mice reported improved healthspan and lifespan and is the source of the drug's reputation. In the Interventions Testing Program, which runs genetically heterogeneous mice at three sites precisely to catch results that do not travel, metformin alone did not significantly extend lifespan in either sex. The combination of metformin with rapamycin is often cited as a success, but the ITP's own paper reports that the male synergy did not reach significance under the protocol-specified test and became significant only in a non-protocol analysis, against historical rather than contemporaneous rapamycin controls.
None of this makes metformin dangerous or useless. It is a good diabetes drug with a long safety record. It does mean that a person taking it to slow ageing is acting on a hypothesis, not a finding, and that the specific trial designed to test the hypothesis has not begun.
The evidence, charted
Fig. 1 · evidence composition
3of 4 citations (75%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 3 distinct years, 2013 to 2019, counted from the citation list on this page. The newest citation on file is from 2019, more than five years ago; the published record may have gone quiet.
Fig. 3 · legal status at a glance
US
Approved
UK
Prescription
AU
Prescription
CA
Prescription
Approved in 1 of 4, prescription route in 3, not approved in 0. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Human2019
Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: the MASTERS trial
94 adults aged 65 and over did 14 weeks of supervised resistance training on 1,700 mg/day metformin or placebo. Placebo gained more lean body mass (p = .003) and thigh muscle mass (p < .001), with greater gains in thigh muscle area (p = .005) and density (p = .020), plus a trend toward blunted strength gains.
Aging Cell - Human2019
Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults
53 adults averaging 62 years did 12 weeks of aerobic training on metformin or placebo, double-blinded. Metformin diminished the training-induced improvements in insulin sensitivity and cardiorespiratory fitness.
Aging Cell - Animal2013
Metformin improves healthspan and lifespan in mice
The positive mouse result that launched metformin's longevity reputation, in C57BL/6 mice. The multi-site Interventions Testing Program, using genetically heterogeneous mice specifically to catch results that do not travel, did not reproduce a significant lifespan effect in either sex.
Nature Communications - Human2014
Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls
The origin of the claim that metformin users outlive non-diabetics. Later replication attempts in Danish registry and twin data, and in a 20 year Welsh cohort, found survival pointing in the opposite direction.
Diabetes, Obesity and Metabolism
What users report
Self-reported experiences, not evidence. Nothing below was measured under controlled conditions, and reports like these cannot separate a real effect from placebo, from the training or diet change that accompanied it, or from what the product actually contained. They are here because knowing what people describe, including what goes wrong, is worth reading alongside the studies.
- Gastrointestinal effects dominate early reports, particularly diarrhoea and abdominal discomfort, and extended-release formulations are widely described as easier to tolerate.
- Vitamin B12 depletion is commonly discussed and is a documented pharmacological effect rather than folklore, with periodic testing frequently recommended in community protocols.
- A recurring debate concerns whether to skip metformin on training days because of the exercise findings. There is no trial testing that strategy, so it is an inference rather than a protocol with evidence behind it.
Sources: Longevity forums, r/longevity and clinic write-ups. Uncontrolled self-report, included for what to expect and watch for, not as evidence of effect.
Frequently asked questions
Does metformin extend lifespan?
There is no randomised human evidence that it does. A 2013 mouse study reported improved lifespan and healthspan and built the drug's reputation, but the multi-site Interventions Testing Program, which uses genetically heterogeneous mice precisely to catch results that do not replicate, did not find a significant lifespan effect in either sex.
Should I take metformin if I lift weights?
Two randomised double-blind trials found metformin reduced the benefit of training in older adults: less lean mass and thigh muscle gained from resistance training, and smaller gains in fitness and insulin sensitivity from aerobic training. If you are taking it for diabetes that is a conversation with your doctor about a drug you need. If you are taking it for longevity while also training, those two goals appear to work against each other.
What about the study showing metformin users outlive people without diabetes?
That 2014 observational analysis is the origin of metformin's longevity reputation. Two later attempts to replicate it, in Danish registry and twin data and in a 20 year Welsh cohort, found the opposite direction. The original also carries several biases that all favour metformin.
Has the TAME trial started?
No. TAME is the trial designed to test metformin as a geroscience drug in 3,000 older adults, and as of September 2026 it has no ClinicalTrials.gov registration, roughly a decade after its design was published. It has had planning funding but not the funding to run.